Bioyond

Headquartered in Shanghai Zhangjiang Science City, Bioyond focuses on intelligent automation transformation within the life sciences sector. The company combines robotics, automation, and artificial intelligence technologies to deliver laboratory automation products and solutions serving pharmaceutical research, clinical diagnostics, and analytical chemistry applications.

Company Overview

Bioyond was established in March 2021 by a founding team with backgrounds from Fortune 500 robotics and life sciences companies. The company has rapidly grown to over 100 employees, with research and development personnel accounting for approximately 70% of the workforce. Team members come from institutions including Peking University, University of Hong Kong, Zhejiang University, Shanghai Jiao Tong University, and international universities such as Rochester Institute of Technology and RWTH Aachen University.

The founding CEO, Tang Yang, previously served as President of ABB Robot China R&D Center and President of ABB Robot China Consumer and Service Robot Business Unit, bringing extensive experience in industrial robotics to the life sciences automation space.

Since inception, Bioyond has completed multiple funding rounds totaling several hundred million RMB. Investors include Sequoia China Seed Fund, Qiming Venture Partners, Lilly Asia Ventures, Boyuan Capital, CICC Capital, Panlin Capital, and Shanghai Zhangjiang Science & Technology Venture Capital. The company has been recognized as a National High-Tech Enterprise and a Shanghai Intelligent Robotics Benchmark Enterprise.

Core Products

LabGenius Robot Platform

The LabGenius platform encompasses multiple robot series designed for laboratory automation:

LabGenius G Series - High-speed, high-precision liquid handling robots featuring modular design. These systems support pipetting, force/position-control grippers, and functional modules including heater-shaker, temperature control, magnetic separation, positive pressure, PCR, HEPA filtration, and UV sterilization.

LabGenius S Series - Material handling robots optimized for labware transfer. The system integrates proprietary trajectory planning and motion control algorithms based on dynamic models, enabling 24/7 unattended sample transport operations.

LabGenius M Series - Mobile composite robots capable of autonomous navigation, obstacle avoidance, and automatic recharging. These units perform long-distance material transfer within and across laboratory spaces.

LabMate Automation Platform

The LabMate series provides compact, modular automation solutions:

LabMate Gleam Series - Standardized liquid handling systems based on LabGenius G Series robots, supporting routine liquid handling, NGS pre-processing, methylation sample preparation, and mass spectrometry sample preparation.

LabMate Polar Series - Transfer automation systems balancing operational speed with human-robot collaboration safety. Features include compact footprint with sufficient plate storage capacity for extended unattended operation.

LabMate Horizon Series - Benchtop all-in-one automation platforms combining LabGenius G Series liquid handling with LabGenius S Series transfer capabilities.

LabMind Software Platform

A unified software ecosystem enabling intelligent scheduling, workflow management, and data integration across laboratory automation systems.

Technology & Innovation

Bioyond’s full-stack robotics platform—spanning motion control, AI visual perception, and force/position hybrid control—gives pharmaceutical and clinical laboratories production-grade automation built on over 200 original patents.

Bioyond maintains three core technology platforms: robotics, automation, and data/cloud computing. The company has developed proprietary technologies including:

• Advanced robot motion control algorithms
• Real-time collision detection systems
• Intelligent path planning
• AI visual perception and positioning
• Force/position hybrid control for precise manipulation

The company holds over 200 original patents and has accumulated extensive industry data enabling “domain cognitive and reasoning” intelligent laboratory robots capable of decision-making in complex research environments.

Market Presence

Bioyond serves over 1,000 customers across pharmaceutical, materials science, agriculture, clinical diagnostics, government research, and academic institutions. Products and solutions are deployed in applications spanning:

• Small molecule drug discovery
• Biologics development
• Cell and gene therapy
• Traditional Chinese medicine research
• Synthetic biology
• Omics research
• Clinical diagnostics
• Materials science

The company has established subsidiaries in the United States and Europe to support international expansion, with products deployed across multiple countries and regions globally.

Key Milestones

• 2021: Company founded in Shanghai Zhangjiang; secured Angel and Pre-A funding from Sequoia China and Qiming Venture Partners
• 2023: Completed Series A and A+ rounds totaling approximately ¥200 million; served over 100 enterprise customers
• 2024: Launched LabGenius G3 and LabGenius S4 next-generation robots; completed Series A3 funding led by Panlin Capital; expanded customer base to over 1,000 clients

Frequently Asked Questions

What types of laboratories does Bioyond serve?

Bioyond provides automation solutions for three main laboratory categories: scientific research laboratories, clinical diagnostic laboratories, and analytical/physical-chemical testing laboratories. Applications include pharmaceutical R&D, clinical sample processing, and materials analysis.

Is Bioyond a medical device company?

Bioyond produces laboratory automation equipment rather than regulated medical devices. Their products automate experimental workflows and sample handling in laboratory settings, supporting research and diagnostic processes without directly performing clinical diagnostic functions.

What differentiates Bioyond from other laboratory automation providers?

Bioyond emphasizes modular, rapidly deployable systems with full-stack proprietary technology including robots, vision systems, force control, and AI-powered scheduling software. The founding team’s industrial robotics background enables reliable, production-grade equipment adapted for life sciences applications.